- Recruiting
NCT04582539: Phase 1/2: Safety and Tolerability of INCB000928 in Myelodysplastic Synd. or Myeloma
NCT04582539: Phase 1/2: To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma.
NCT04582539: Phase 1/2: To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma.
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.
Sponsor
ClinicalTrials.gov Identifier: NCT04582539
Official Title: A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma
First Posted : October 9, 2020
Click here to see details on ClinicalTrials.gov
Drug: INCB000928
ALK2 Inhibitor INCB000928 (Code C175551)
ALK2 Inhibitor INCB000928
INCB 000928
INCB-000928
INCB000928
Locations
United States, California
United States, Florida
United States, Louisiana
United States, Michigan
United States, Ohio
United States, Tennessee
United States, Texas
Europe
France
Italy